These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 32957974)

  • 41.
    Wei W; Sun J; Zhang H; Xiao X; Huang C; Wang L; Zhong H; Jiang Y; Zhang X; Jiang G
    Cancer Res; 2021 Dec; 81(24):6142-6156. PubMed ID: 34702726
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.
    Liao RG; Jung J; Tchaicha J; Wilkerson MD; Sivachenko A; Beauchamp EM; Liu Q; Pugh TJ; Pedamallu CS; Hayes DN; Gray NS; Getz G; Wong KK; Haddad RI; Meyerson M; Hammerman PS
    Cancer Res; 2013 Aug; 73(16):5195-205. PubMed ID: 23786770
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells.
    Hänze J; Kessel F; Di Fazio P; Hofmann R; Hegele A
    Biomed Pharmacother; 2018 Oct; 106():316-325. PubMed ID: 29966976
    [TBL] [Abstract][Full Text] [Related]  

  • 45. EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer.
    Okamura S; Yoshino H; Kuroshima K; Tsuruda M; Osako Y; Sakaguchi T; Yonemori M; Yamada Y; Tatarano S; Nakagawa M; Enokida H
    BMC Cancer; 2021 Jan; 21(1):48. PubMed ID: 33430801
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer.
    Kubo N; Harada T; Shiraishi Y; Nosaki K; Nakagaki N; Takeshita M; Ouchi H; Iwama E; Tanaka K; Okamoto I; Sasaki H; Nakanishi Y
    Anticancer Res; 2019 Feb; 39(2):671-677. PubMed ID: 30711944
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
    Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Loss of UTX/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer.
    Barrows D; Feng L; Carroll TS; Allis CD
    Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25732-25741. PubMed ID: 32989154
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A place for precision medicine in bladder cancer: targeting the FGFRs.
    di Martino E; Tomlinson DC; Williams SV; Knowles MA
    Future Oncol; 2016 Oct; 12(19):2243-63. PubMed ID: 27381494
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.
    Pan CX; Zhang H; Tepper CG; Lin TY; Davis RR; Keck J; Ghosh PM; Gill P; Airhart S; Bult C; Gandara DR; Liu E; de Vere White RW
    PLoS One; 2015; 10(8):e0134346. PubMed ID: 26270481
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation.
    Nelson KN; Meyer AN; Siari A; Campos AR; Motamedchaboki K; Donoghue DJ
    Mol Cancer Res; 2016 May; 14(5):458-69. PubMed ID: 26869289
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic Profiles Associated with Chemoresistance in Patient-Derived Xenograft Models of Ovarian Cancer.
    Li LY; Kim HJ; Park SA; Lee SH; Kim LK; Lee JY; Kim S; Kim YT; Kim SW; Nam EJ
    Cancer Res Treat; 2019 Jul; 51(3):1117-1127. PubMed ID: 30428638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827-TR.
    Yu T; Xia Q; Gong T; Wang J; Zhong D
    Thorac Cancer; 2020 May; 11(5):1129-1138. PubMed ID: 32163227
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oncogenic FGFR3 gene fusions in bladder cancer.
    Williams SV; Hurst CD; Knowles MA
    Hum Mol Genet; 2013 Feb; 22(4):795-803. PubMed ID: 23175443
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug-sensitive FGFR3 mutations in lung adenocarcinoma.
    Chandrani P; Prabhash K; Prasad R; Sethunath V; Ranjan M; Iyer P; Aich J; Dhamne H; Iyer DN; Upadhyay P; Mohanty B; Chandna P; Kumar R; Joshi A; Noronha V; Patil V; Ramaswamy A; Karpe A; Thorat R; Chaudhari P; Ingle A; Choughule A; Dutt A
    Ann Oncol; 2017 Mar; 28(3):597-603. PubMed ID: 27998968
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.
    Liu D; Abbosh P; Keliher D; Reardon B; Miao D; Mouw K; Weiner-Taylor A; Wankowicz S; Han G; Teo MY; Cipolla C; Kim J; Iyer G; Al-Ahmadie H; Dulaimi E; Chen DYT; Alpaugh RK; Hoffman-Censits J; Garraway LA; Getz G; Carter SL; Bellmunt J; Plimack ER; Rosenberg JE; Van Allen EM
    Nat Commun; 2017 Dec; 8(1):2193. PubMed ID: 29259186
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER
    Mao P; Cohen O; Kowalski KJ; Kusiel JG; Buendia-Buendia JE; Cuoco MS; Exman P; Wander SA; Waks AG; Nayar U; Chung J; Freeman S; Rozenblatt-Rosen O; Miller VA; Piccioni F; Root DE; Regev A; Winer EP; Lin NU; Wagle N
    Clin Cancer Res; 2020 Nov; 26(22):5974-5989. PubMed ID: 32723837
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells.
    Yokoyama N; Matsunobu T; Matsumoto Y; Fukushi JI; Endo M; Hatano M; Nabeshima A; Fukushima S; Okada S; Iwamoto Y
    Sci Rep; 2017 Mar; 7():45332. PubMed ID: 28350009
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
    Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
    Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era.
    Bellmunt J; Esteban E; Del Muro XG; Sepúlveda JM; Maroto P; Gallardo E; Del Alba AG; Etxaniz O; Guix M; Larriba JLG; Arranz JA; Redrado M; Calvo A
    Eur Urol Oncol; 2021 Jun; 4(3):502-505. PubMed ID: 31477526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.